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Enzyme replacement therapy with taliglucerase alfa:
36-month safety and efficacy results in adult patients with
Gaucher disease previously treated with imiglucerase
Gregory M. Pastores,1* Suma P. Shankar,2,3 Milan Petakov,4 Pilar Giraldo,5 Hanna Rosenbaum,6 Dominick J. Amato,7
Jeffrey Szer,8 Raul Chertkoff,9 Einat Brill-Almon,9 and Ari Zimran10
Taliglucerase alfa is the first available plant cell-expressed human recombinant therapeutic protein. It is
indicated for treatment of patients with type 1 Gaucher disease (GD) in adult and pediatric patients in several
countries. Study PB-06-002 examined the safety and efficacy of taliglucerase alfa for 9 months in patients
who previously received imiglucerase. The results of adult patients from Study PB-06-002 who continued
receiving taliglucerase alfa in extension Study PB-06-003 for up to 36 months are reported here. Eighteen
patients received at least one dose of taliglucerase alfa in Study PB-06-003; 10 patients completed 36 total
months of therapy, and four patients who transitioned to commercial drug completed 30–33 months of
treatment. In patients who completed 36 total months of treatment, mean percent (6standard error) changes
from baseline/time of switch to taliglucerase alfa to 36 months were as follows: hemoglobin concentration,
21.0% (61.9%; n5 10); platelet count, 19.3% (69.8%; n5 10); spleen volume measured in multiples of normal
(MN), 219.8% (69.9%; n5 7); liver volume measured in MN, 10.9% (65.4%; n58); chitotriosidase activity,
251.5% (68.1%; n5 10); and CCL18 concentration, 236.5 (68.0%; n5 10). Four patients developed antidrug
antibodies, including one with evidence of neutralizing activity in vitro. All treatment-related adverse events
were mild or moderate and transient. The 36-month results of switching from imiglucerase to taliglucerase alfa
treatment in adults with GD provide further data on the clinical safety and efficacy of taliglucerase alfa beyond
the initial 9 months of the original study. www.clinicaltrials.gov identifier NCT00705939.
Am. J. Hematol. 91:661–665, 2016. VC 2016 The Authors. American Journal of Hematology Published by Wiley Periodicals, Inc.
 Introduction
Gaucher disease (GD), caused by acid beta-glucosidase deficiency, results in the accumulation of glucocerebroside in macrophages and other
cell types leading to splenomegaly, hepatomegaly, anemia, and thrombocytopenia [1,2]. For patients with type 1 (nonneuronopathic) GD, enzyme
replacement therapy (ERT) has been the standard of care for more than 20 years [3].
The necessity of additional ERT options for patients with GD became apparent during the shortage of imiglucerase in 2009 [4,5]. Taliglucerase
alfa is the first FDA-approved plant cell-expressed human recombinant therapeutic protein [6] and is indicated for treatment of adults with type 1
GD in the United States, Israel, Brazil, Australia, Canada, Chile, and other countries; it is also approved for treatment of children in the United
States, Australia, Canada, Israel, Mexico, and other countries, and for hematologic manifestations in pediatric patients with type 3 GD in Canada.
The taliglucerase alfa production system offers the ability for rapid scale-up and is not susceptible to contamination with mammalian pathogens
[7]. The current report expands the database of the long-term safety and efficacy of taliglucerase alfa in patients who have been previously treated
with imiglucerase.
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Study PB-06-002 (NCT00712348) [8] was a phase III, 9-month,
multicenter, open-label, switchover trial of taliglucerase alfa in adult
and pediatric patients with GD who had achieved disease stability
with imiglucerase. Patients were switched from imiglucerase to the
same dose of taliglucerase alfa for 9 months [9]. Hemoglobin concen-
tration, platelet count, spleen volume, and liver volume remained
unchanged and treatment-related adverse events (AEs) were mild or
moderate in severity and transient in nature [9]. Adult patients who
completed Study PB-06-002 were eligible to participate in extension
Study PB-06-003 (NCT00705939) [8,10]. The objective of the present
analysis was to continue to follow the efficacy and safety of taliglucer-
ase alfa through 36 total months of treatment.
 Patients and Methods
Study design. This analysis evaluated the efficacy and safety of taliglucerase alfa
treatment for adult patients with stable GD in the 9-month, phase III, multicenter,
open-label Study PB-06-002 (pivotal “switchover study”) and its extension study
PB-06-003, which included patients previously treated with imiglucerase. The
design of “switchover study” PB-06-002 has been published [9]; it incorporated a
prospective 12-week GD stability evaluation period for patients while on imiglucer-
ase. Enrollment had been open during the period of imiglucerase shortage and,
therefore, historical data were used to enable immediate treatment with taliglucerase
alfa in eligible patients whose treatments were at risk for interruption. In the pres-
ent report, data were analyzed from patients who completed Study PB-06-002 (9
months of treatment) and continued in Study PB-06-003 (27 months of treatment)
for a total duration of up to 36 months of taliglucerase alfa treatment.
The study protocol and the informed consent form were reviewed and approved
by the ethics committees/institutional review boards (IRBs) for each study site; pro-
tocol amendments were approved by the IRBs prior to implementation. This study
was conducted in accordance with the International Conference on Harmonisation
Good Clinical Practice guidelines and all local regulations. Written informed con-
sent was obtained for all patients.
Patients. The main inclusion criteria were completion of Study PB-06-002 and
written informed consent to continue in Study PB-06-003. Inclusion criteria for
Study PB-06-002 included age 2 years, treatment with imiglucerase for 2 years,
and being on a stable dose of imiglucerase for at least 6 months preceding study
enrollment. Patients were also required to have stable GD determined during the
12-week stability evaluation period for all patients except for those affected by the
2009 imiglucerase shortage, for whom historical data were used. Disease stability
was based on criteria that implicated no clinically meaningful variation in labora-
tory values of hemoglobin and platelet counts or in liver and spleen volumes (see
Supporting Information).
The main exclusion criteria from Study PB-06-002 affecting patients in this
analysis were a previous infusion reaction to imiglucerase or alglucerase; presence
of human immunodeficiency virus; hepatitis B surface antigen and/or hepatitis C
infections; and unresolved anemia due to iron, folic acid, or vitamin B12 deficiency.
Exclusion criteria for Study PB-06-003 included taking another experimental medi-
cation (for any disease), and presence of any condition that would interfere with
compliance with study requirements as judged by the investigator.
Study treatment. Taliglucerase alfa was administered by intravenous infusion at
2-week intervals. Patients started receiving taliglucerase alfa in Study PB-06-002 at
the dosage equivalent to the patient’s imiglucerase dose at screening or prior to the
imiglucerase shortage. In Study PB-06-003, each patient continued treatment with
the same dose of taliglucerase alfa the patient was receiving at the completion of
Study PB-06-002. If a clinically relevant deterioration occurred in either Study PB-
06-002 or Study PB-06-003, the dose for that patient could be increased up to 60
U/kg or treatment could be discontinued as previously described [9]. Patients could
exit the study upon marketing approval in their country and transition to a com-
mercially available drug.
Assessments. Efficacy evaluations included hemoglobin concentration, platelet
count, spleen volume, liver volume, and biomarkers (chitotriosidase activity and
chemokine [C-C motif] ligand 18 [CCL18] concentration). Organ volumes were
determined via magnetic resonance imaging using a validated system as previously
described with two readers blinded to treatment group, patient number, and
sequence [11,12]. Two patients were unable to tolerate magnetic resonance imaging
procedures and were excluded from the organ volume analyses; their organ vol-
umes were monitored using ultrasonography. Another patient had a pre-existing
splenectomy and was excluded from the spleen volume analysis. Safety was assessed
as previously described [9].
Statistical analysis. Descriptive statistics for continuous variables, sample size
(n), mean and its standard error (SE), standard deviation, median, and range were
calculated for hemoglobin concentration, platelet count, spleen volume, liver vol-
ume, and change in biomarker activity. Spleen and liver volumes were calculated as
multiples of normal (MN) where normal spleen volume is 2 mL/kg of body weight
and normal liver volume is 25 mL/kg of body weight. For categorical variables,
count and percentages are presented. Time points were counted continuously from
baseline at the start of Study PB-06-002 through Study PB-06-003. No inferential
statistics were performed for testing the change from baseline and/or for comparing
between or among treatment groups because of the small number of patients. For
each parameter, efficacy analyses included those patients for whom data were avail-
able at each time point. The safety population included all patients originally




Patient disposition is provided in Supporting Information Fig. S1.
A total of 19 adult patients from Study PB-06-002 were enrolled in
extension Study PB-06-003. One patient was noncompliant after sign-
ing the informed consent form and was excluded from the study
prior to receiving the study drug. A total of 18 patients received treat-
ment in Study PB-06-003. Four patients discontinued the study for
different reasons: (1) move to the compassionate use program for tali-
glucerase alfa after 28 infusions; (2) withdrew to pursue another clini-
cal study after 25 infusions; (3) dissatisfaction with the results of
treatment after 15 infusions despite lack of objective parameters of
deterioration; and (4) protocol violation (refusal to return to all end-
of-study visits) after 44 infusions. During this study, marketing
approval for taliglucerase alfa occurred in the countries of four addi-
tional patients and, per protocol, these four patients exited the study
and continued treatment with commercially available taliglucerase
alfa. Treatment for these latter patients ranged from 30 to 33 total
months across Studies PB-06-002 and PB-06-003.
Patients received taliglucerase alfa at the same dose as imiglucerase.
The mean (standard error [6SE]) taliglucerase alfa dose was 32.4
(63.9) U/kg (range, 12.0–59.0 U/kg) in the population of all patients
who received taliglucerase alfa in the extension study (n5 18), with
four patients receiving 15 U/kg, seven patients receiving >15 U/kg
to 30 U/kg, and seven patients receiving >30 U/kg.
Baseline patient demographics and disease characteristics are shown
in Supporting Information Tables SI and SII. All of the patients were
Caucasian, half were male, and approximately two thirds were of Ashke-
nazi Jewish ethnicity. A similar demographic profile was observed in the
population of 10 patients who had completed 36 months of treatment.
Efficacy results
Individual and mean efficacy parameters are shown in Figs. 1–3;
detailed individual patient efficacy data can be found in Supporting
Information Tables SIII and SIV.
Mean hemoglobin concentration was unchanged through 36 months
of treatment with taliglucerase alfa (Fig. 1A). For the 10 patients who
completed 36 months of treatment, mean absolute change (6SE) in
hemoglobin concentration from baseline to 36 months was20.2 (60.3)
g/dL, which represented a mean percentage change of 21.0% (61.9%).
Although some variations were observed within the 36 months of ther-
apy for individual patients, hemoglobin concentration for each tended
to be similar at month 36 compared with that at baseline (Fig. 1A).
Mean platelet count was unchanged through 36 months of treatment
with taliglucerase alfa (Fig. 1B). For most of the 10 patients who completed
36 months of taliglucerase alfa treatment, platelet counts remained at simi-
lar levels at month 36 to those during imiglucerase treatment. The mean
absolute change (6SE) in platelet count from baseline to 36 months was
23,800/mm3 (610,072/mm3), which represented a nominal change.
Spleen and liver volumes were unchanged or decreased through 36
months of treatment with taliglucerase alfa (Fig. 2). For the patients with
available data who completed 36 months of treatment (n5 7), mean
absolute change (6SE) in spleen volume from baseline to 36 months was
21.3 (60.9) MN, which represented a mean percentage change in
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volume (measured in MN) of 219.8% (69.9%). There was no change in
mean liver volume (measured in MN) across the patients with available
data who completed 36 months of treatment. Most of the patients (n5 8)
maintained a liver volume <1.5 MN, consistent with the therapeutic goal
for hepatomegaly [13].
Chitotriosidase decreased by last observation for all patients
assessed (Fig. 3A). Mean chitotriosidase activity (6SE) was 12,206
(64,934) nmol/mLhr at baseline and 6,551 (63,018) nmol/mLhr at
36 months (n5 10). This represented a mean (6SE) decrease in chi-
totriosidase activity of 51.5% (68.1%) from baseline to 36 months.
CCL18 decreased by last observation for most patients (Fig. 3B). One
patient (23-206) had a higher CCL18 level at the end of the study
than at baseline but had lower chitotriosidase activity at study end.
Mean CCL18 concentration (6SE) was 447.3 (699.0) ng/mL at base-
line; mean levels changed by 236.5% (68.0%) from baseline to
month 36 (n5 10).
Safety
Overall AE results for the safety population (n5 18) are listed in
Table I. Almost all AEs were mild to moderate in severity and tran-
sient. Serious AEs were reported in three patients, but none were
considered to be treatment-related. One patient (14-216) had right
gonarthrosis at baseline and developed left knee pain during the
study; both knees were replaced with prostheses during the study.
Another patient (20-220) underwent renal stone removal and a third
patient (15-222) had traumatic rib fracture and pneumothorax.
Antidrug antibodies
Four patients (14-210, 20-211, 20-220, and 22-226) tested positive
for the presence of anti-taliglucerase alfa IgG antibodies on at least one
visit. Patient 14-210 tested positive at months 3–30 with a maximal IgG
titer at month 27, patient 20-211 tested positive at months 18–27 with a
maximal IgG titer at month 18, and patient 22-226 tested positive at
months 3, 6, and 18 with a maximal IgG titer at month 3. Patient 20-
220 tested positive at months 6–18 with a maximal IgG titer at month
18 and was found to have neutralizing antibodies between months 6
and 18 based on an in vitro enzymatic activity assay but was negative in
a cell-based assay. The other three patients tested negative for neutraliz-
ing activity. Disease parameters for these patients at baseline and last
observation are available in Supporting Information Tables SIII and
SIV. The significance of these findings is unclear at this time.
 Discussion
In the present report of adult patients with type 1 GD receiving
taliglucerase alfa following previous treatment with imiglucerase,
hemoglobin concentration, platelet count, and liver volume remained
unchanged while spleen volume remained unchanged or improved
Figure 1. (A) Hemoglobin concentration and (B) platelet count during long-
term treatment with taliglucerase alfa. Values are shown for each patient
from baseline to last observation or through 36 total months of treatment.
Mean values represent the patients who completed 36 months of treatment
(n5 10).
Figure 2. (A) Spleen volume, expressed as multiples of normal (MN),
where normal spleen volume is 2 mL/kg of body weight (kg), and (B) liver
volume, expressed as MN, where normal liver volume is 25 mL/kg of body
weight (kg), during long-term treatment with taliglucerase alfa. Values are
shown for each patient from baseline to last observation or through 36
total months of treatment. One patient was splenectomized and not
included in spleen volume analysis; two patients were unable to tolerate
MRI procedures and were not included in spleen volume or liver volume
analyses but were followed by ultrasound. Mean values represent the
patients with available data who completed 36 months of treatment
(spleen, n5 7; liver, n58). MRI, magnetic resonance imaging.
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after a total of up to 36 months of treatment. Reductions were
observed in the biomarkers chitotriosidase and CCL18. These findings
indicate that the clinical stability of GD parameters previously
reported in the first 9 months of treatment with taliglucerase alfa fol-
lowing previous treatment with imiglucerase [9] was sustained during
longer-term follow-up in the present study. The AE findings did not
present any new safety issues. Most AEs were mild or moderate and
transient in nature.
Only one patient (20-220) experienced AEs considered to be
related to treatment, which were mild flushing, discomfort, and skin
tightness, all occurring within 24 hr of the seventh infusion. The
patient continued treatment without recurrence and without pre-
medication; the patient received an average dose of 31.8 U/kg and
discontinued the study after the 44th infusion (due to protocol viola-
tion of refusing to return to all end-of-study visits), well after resolu-
tion of these events. This patient tested positive for neutralizing
antibodies between months 6 and 18. This patient also underwent
surgical renal stone removal, missed an infusion, but resumed ther-
apy. Later, the patient discontinued therapy, refusing to return for all
end-of-study visits because of time constraints. At baseline and last
observation, respectively (see Supporting Information Table SIII),
hemoglobin concentration was 15.5 and 13.9 g/dL, platelet count was
132,333/mm3 and 80,000/mm3, spleen volume was 6.9 MN and 6.3
MN, and liver volume was 0.9 MN and 0.8 MN; chitotriosidase activ-
ity was not available (not conducted at baseline).
Two other patients discontinued the study. One of these patients
(23-204; average dose, 28.8 U/kg) experienced one AE (wasp sting,
not related to treatment). The patient decided to pursue another
experimental medication after 20 total months of treatment; at base-
line and last observation, respectively (see Supporting Information
Table SIII), hemoglobin concentration was 16.1 and 15.6 g/dL, plate-
let count was 217,167/mm3 and 203,000/mm3, spleen volume was 2.3
MN and 2.0 MN, liver volume was 0.7 MN at both time points, and
chitotriosidase activity was reduced by 32.6% from a baseline of 448
nmol/mLhr.
The other patient (10-201; average dose, 19.9 U/kg) discontinued
after 16 total months of treatment with taliglucerase alfa because of
dissatisfaction with treatment; at baseline and last observation for
each parameter, respectively (see Supporting Information Table SIII),
hemoglobin concentration was 11.2 and 10.6 g/dL, platelet count was
60,667/mm3 and 41,000/mm3, spleen volume was 20.5 MN at both
time points, liver volume was 1.3 MN and 1.2 MN, with a 6.4%
reduction in chitotriosidase activity from a baseline value of 15,209
nmol/mLhr. None of the patients who completed 36 months of treat-
ment experienced an AE considered to be related to taliglucerase alfa
treatment.
It should be noted that the relatively broad range in the bio-
markers reflects different baseline parameters of the patients entering
the trial, such as different disease severities, different genotypes, and
various ERT dosage regimens. The significance of the findings of
anti-taliglucerase alfa antibodies in four patients in this study is not
clear. Comparison of the incidence of antibodies to taliglucerase alfa
with the incidence of antibodies to other products may be misleading.
This is because immunogenicity assay results can be highly dependent
upon or influenced by extrinsic and intrinsic factors such as the sen-
sitivity and specificity of the assay, assay methodology including sam-
ple handling as well as timing of sample collection, concomitant
medication, and underlying disease [14]. The limitations of this study
lie primarily in its small size, which is common for studies of
“orphan drugs” such as ERT for GD.
In conclusion, following 3-year treatment with taliglucerase alfa in
adult patients with type 1 GD who were previously treated with imi-
glucerase, mean organ volume and hematologic values were
unchanged or improved. In addition, further reductions in both
spleen volume and biomarkers were observed in several patients in
this study. These results extend the clinical safety and efficacy profile
of taliglucerase alfa. A major limitation of the study is the small num-
ber of patients assessed.
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Figure 3. Percentage change in (A) chitotriosidase activity and (B) CCL18
concentration during long-term treatment with taliglucerase alfa. Values
are shown for each patient from baseline to last observation or through
36 total months of treatment. Mean values represent the patients who
completed 36 months of treatment (n5 10).







Total 136 (17) 100 (94.4)
Mild or moderate
in severity
134 (17) 98.5 (94.4)
Severe or very severe 2 (2) 1.5 (11.1)
Non–treatment-related 133 (17) 97.8 (94.4)
Treatment-related 3 (1) 2.2 (5.6)
a The most common adverse events were nasopharyngitis (n5 7), pyrexia
(n54), arthralgia (n5 4), diarrhea (n53), vomiting (n53), upper respiratory
tract infection (n5 3), cough (n53), and musculoskeletal pain (n53).
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